Chen Y, Wiesmann C, Fuh G, Li B, Christinger H W, McKay P, de Vos A M, Lowman H B
Department of Protein Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
J Mol Biol. 1999 Nov 5;293(4):865-81. doi: 10.1006/jmbi.1999.3192.
The Fab portion of a humanized antibody (Fab-12; IgG form known as rhuMAb VEGF) to vascular endothelial growth factor (VEGF) has been affinity-matured through complementarity-determining region (CDR) mutation, followed by affinity selection using monovalent phage display. After stringent binding selections at 37 degrees C, with dissociation (off-rate) selection periods of several days, high affinity variants were isolated from CDR-H1, H2, and H3 libraries. Mutations were combined to obtain cumulatively tighter-binding variants. The final variant identified here, Y0317, contained six mutations from the parental antibody. In vitro cell-based assays show that four mutations yielded an improvement of about 100-fold in potency for inhibition of VEGF-dependent cell proliferation by this variant, consistent with the equilibrium binding constant determined from kinetics experiments at 37 degrees C. Using X-ray crystallography, we determined a high-resolution structure of the complex between VEGF and the affinity-matured Fab fragment. The overall features of the binding interface seen previously with wild-type are preserved, and many contact residues are maintained in precise alignment in the superimposed structures. However, locally, we see evidence for improved contacts between antibody and antigen, and two mutations result in increased van der Waals contact and improved hydrogen bonding. Site-directed mutants confirm that the most favorable improvements as judged by examination of the complex structure, in fact, have the greatest impact on free energy of binding. In general, the final antibody has improved affinity for several VEGF variants as compared with the parental antibody; however, some contact residues on VEGF differ in their contribution to the energetics of Fab binding. The results show that small changes even in a large protein-protein binding interface can have significant effects on the energetics of interaction.
一种针对血管内皮生长因子(VEGF)的人源化抗体(Fab-12;IgG形式,称为rhuMAb VEGF)的Fab部分通过互补决定区(CDR)突变实现亲和力成熟,随后使用单价噬菌体展示进行亲和力选择。在37℃进行严格的结合选择,并进行数天的解离(解离速率)选择期后,从CDR-H1、H2和H3文库中分离出高亲和力变体。将突变组合以获得结合更紧密的累积变体。此处鉴定出的最终变体Y0317含有来自亲本抗体的六个突变。基于细胞的体外试验表明,四个突变使该变体抑制VEGF依赖性细胞增殖的效力提高了约100倍,这与在37℃下通过动力学实验确定的平衡结合常数一致。利用X射线晶体学,我们确定了VEGF与亲和力成熟的Fab片段之间复合物的高分辨率结构。先前在野生型中看到的结合界面的总体特征得以保留,并且许多接触残基在叠加结构中保持精确对齐。然而,在局部,我们看到抗体与抗原之间接触改善的证据,并且两个突变导致范德华接触增加和氢键改善。定点突变证实,通过检查复合物结构判断最有利的改善实际上对结合自由能有最大影响。一般来说,与亲本抗体相比,最终抗体对几种VEGF变体的亲和力有所提高;然而,VEGF上的一些接触残基对Fab结合能量学的贡献不同。结果表明,即使在大的蛋白质-蛋白质结合界面中发生小的变化也会对相互作用的能量学产生显著影响。